» Articles » PMID: 38409566

Evaluation of Electrocardiogram Parameters and Heart Rate Variability During Blood Pressure Elevation by Phenylephrine in Cirrhotic Rats

Overview
Date 2024 Feb 27
PMID 38409566
Authors
Affiliations
Soon will be listed here.
Abstract

Cirrhotic cardiomyopathy is a myocardial disease that may go undetected in the early stages due to peripheral vasodilatation. The aim of the study was to evaluate the electrocardiogram (ECG) and heart rate variability (HRV) after raising blood pressure by phenylephrine injection in rats with liver cirrhosis. Twenty male Sprague-Dawley rats were divided into the Sham and common bile duct ligation (CBDL) groups. After 44 days, animals were anesthetized and the right femoral artery and vein catheterized. After a steady-state period, a bolus injection of phenylephrine (PHE, 10 μg/μl/IV, baroreflex maneuver) was followed by a slow injection of PHE (100 μg/ml/5 min/IV, sustained maneuver). Rapid and slow injections of PHE resulted in a greater increase in mean arterial pressure (MAP) and a weaker bradycardia response in the CBDL group than in the Sham group. ECG analysis showed increased QT, QTc, JT, and T peak to T end in the CBDL group, which remained unchanged after PHE injection. On the other hand, the parasympathetic indices of the HF band and RMSSD, and the sympathetic index of the LF band after PHE injection were lower in the CBDL group than in the Sham group.ECG data indicated prolonged ventricular depolarization and repolarization, independent of blood pressure levels in cirrhosis. On the other hand, after PHE injection, the parasympathetic and sympathetic components of HRV decreased, regardless of the duration of elevated blood pressure. We suggest that HRV analysis can provide a useful approach to assess cardiac dysfunction associated with elevated blood pressure in cirrhosis.

Citing Articles

Modelling hemodynamics regulation in rats and dogs to facilitate drugs safety risk assessment.

Morris C, Rolf M, Starnes L, Villar I, Pointon A, Kimko H Front Pharmacol. 2024; 15:1402462.

PMID: 39534082 PMC: 11555398. DOI: 10.3389/fphar.2024.1402462.

References
1.
Henriksen J, Moller S, Schifter S, Abrahamsen J, Becker U . High arterial compliance in cirrhosis is related to low adrenaline and elevated circulating calcitonin gene related peptide but not to activated vasoconstrictor systems. Gut. 2001; 49(1):112-8. PMC: 1728353. DOI: 10.1136/gut.49.1.112. View

2.
Liu H, Gaskari S, Lee S . Cardiac and vascular changes in cirrhosis: pathogenic mechanisms. World J Gastroenterol. 2006; 12(6):837-42. PMC: 4066146. DOI: 10.3748/wjg.v12.i6.837. View

3.
Moller S, Bendtsen F . The pathophysiology of arterial vasodilatation and hyperdynamic circulation in cirrhosis. Liver Int. 2017; 38(4):570-580. DOI: 10.1111/liv.13589. View

4.
Iwakiri Y, Groszmann R . The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology. 2006; 43(2 Suppl 1):S121-31. DOI: 10.1002/hep.20993. View

5.
Moller S, Lee S . Cirrhotic cardiomyopathy. J Hepatol. 2018; 69(4):958-960. DOI: 10.1016/j.jhep.2018.01.006. View